Notes

A good article around the nominal versus. genuine definitions of aging.
PURPOSE To study the efficacy of bevacizumab combined with nedaplatin in the treatment of ovarian cancer and its effects on tumor markers and immunity of patients. METHODS A total of 100 ovarian cancer patients treated in our hospital from January 2015 to December 2018 were enrolled and divided into experimental group (n=50) and control group (n=50) using a random number table. Patients in the control group were treated with carboplatin alone, while those in the experimental group were treated with bevacizumab combined with nedaplatin, based on the treatment in the control group. The efficacy, adverse reactions and quality of life (QoL) score of patients were observed. Moreover, the levels of serum human epididymis protein 4 (HE4), alpha fetoprotein (AFP) and macrophage migration inhibitory factor (MIF), tumor markers carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA) and CA19.9, immunity indexes cluster of differentiation 3+ (CD3+), CD4+, CD8+ and natural killer (NK) cells, and serum inflammatory factors interleukin-8 (IL-8), IL-6 and IL-10 were detected before and after therapy. RESULTS In the experimental group, the efficacy was superior to that in control group (p0.05). Ivarmacitinib After treatment, the levels of HE4, AFP and MIF, CA125, CEA and CA19.9 and inflammatory factors IL-8, IL-6 and IL-10 obviously declined in the experimental group compared with the control group (p less then 0.05), while the levels of immunity indexes CD3+, CD4+, CD8+ and NK cells were clearly increased (p less then 0.05). CONCLUSION Bevacizumab combined with nedaplatin has good efficacy in the treatment of ovarian cancer, which can significantly improve the tumor markers, enhance the immunity and ameliorate the QoL of patients, with fewer adverse reactions, so it is worthy of popularization and application.PURPOSE Tormentic acid has been shown to exert remarkable anti-cancer potential against different cancer cell types. In this study, the anti-cancer potential of tormentic acid was examined in cisplatin-resistant cervical cancer cells (HeLa cells). Further, the effects of tormentic acid on cell cycle, reactive oxygen species (ROS) production, and mTOR/PI3K/AKT signalling pathway were evaluated as well. METHODS Cell viability was evaluated by MTT assay and its impact on mTOR/PI3K/AKT signalling pathway was estimated via western blot assay. Colony formation was analysed through clonogenic assay and phase-contrast microscopy was used for the determination of apoptotic cell morphology along with DAPI staining. Fluorescence-activated cell sorting was performed for cell cycle analysis and ROS production was monitored by fluorescence microscopy. RESULTS The results indicated that tormentic acid significantly supresses the proliferation of HeLa cells. These antiproliferative effects of tormentic acid were dose-dependeand targeting of mTOR/PI3K/AKT signalling pathway. Thus, tormentic acid may be considered as a lead molecule in cancer therapeutics.PURPOSE Although pain is a common event during treatment of cancer, its assessment and management remains suboptimal in everyday clinical practice at global level. METHODS Considering both the important role of internet in daily life and that clinical guidelines are important for translating evidence in clinical practice, we performed a prospective study to scrutinize the magnitude of updated evidence-based cancer-pain guideline recommendation for physicians on the web. Changes over-time at a global level were scrutinized at two time points 2011 for baseline and 2018 at first follow-up. Both anesthesiology and oncology societies were analyzed. RESULTS In 2011 we scrutinized 181,00 WebPages and 370 eligible societies were identified; 364 of these were eligible for analyses both in 2011 and 2018. The magnitude of cancer pain updated and evidence-based guideline recommendations on the web for health care providers was extremely low at global level and at any time point considered 1.1% (4/364) in 2011 and 4.7% (17/364) in 2018. Continental and intercontinental patterns, National's highest developmental index, oncology tradition and economic-geographic areas were not found to influence cancer pain web-guideline provision. In 2018, pain & supportive care societies provided the highest rate of updated evidence-based cancer-pain guidelines for clinicians. Only 3/25 medical oncology societies and 1/34 radiation oncology societies, provided own or e-link (to other societies') evidence-based guidelines in their websites. CONCLUSIONS Major medical oncology and radiation oncology societies - at global level - fail to produce updated cancer pain recommendations for their physicians, with most of these providing no or inconsistent or outdated guidelines.PURPOSE Surgical resection is the cornerstone of curative treatment for rectal adenocarcinomas. For extensive invasive tumors, preoperative radiotherapy and chemoradiotherapy have been utilized to promote tumor regression in an attempt to convert a planned abdominoperineal resection to a sphincter-sparing surgical procedure. In order to find out which of the currently radiation therapy treatment regimen used preoperatively for rectal cancer is the best we conducted a comprehensive literature search. METHODS We searched the Cochrane Register of Controlled Trials (CENTRAL), MEDLINE and EMBASE database up to December 2018 for trials comparing the short and long term radiation therapy regimens for rectal carcinoma associated or not with chemotherapy. RESULTS The search of the literature identified 38 papers related to the subject. After analysis and evaluation, 11 eligible trials were included for review. The optimal fractionation and timing of surgery in relation to radiotherapy was still controversial. Randomized trials showed that if surgery is delayed after 5×5 Gy and consolidation chemotherapy is added between 5×5 Gy and surgery, such a combination results in better short term overall survival and lower acute toxicity. CONCLUSION Long-course radiotherapy with delay seems not to be different than short-course radiotherapy with delay, but prolongs substantially the treatment time.
Website: https://www.selleckchem.com/products/shr0302.html